Company news

Syndax Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

May 11, 2025

Syndax Announces Participation in May Investor Conferences

May 7, 2025

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

May 6, 2025

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

April 27, 2025

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

April 1, 2025

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 2, 2025

Syndax Announces Participation in March Investor Conferences

February 24, 2025

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

February 23, 2025

Syndax Announces Participation in February Investor Conferences

January 29, 2025

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

January 14, 2025

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

January 12, 2025

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

December 8, 2024

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

December 6, 2024

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference

November 26, 2024

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

November 14, 2024

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

November 11, 2024

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update

November 4, 2024

Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024

November 4, 2024

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting

November 4, 2024

Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

November 4, 2024

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

November 3, 2024

Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024

October 28, 2024

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

September 17, 2024

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

August 13, 2024

Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

August 11, 2024

Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update

July 31, 2024

Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia

July 28, 2024

Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024

July 24, 2024

Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

June 13, 2024

Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

June 5, 2024

Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

May 14, 2024

Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference

May 8, 2024

Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

May 7, 2024

Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

April 30, 2024

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

April 9, 2024

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

April 7, 2024

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

March 27, 2024

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

March 25, 2024

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

March 17, 2024

Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

February 26, 2024

Syndax Announces Participation at Two Upcoming Investor Conferences

February 25, 2024

Syndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024

February 19, 2024

Syndax Highlights Recent Updates and Anticipated 2024 Milestones

January 1, 2024

Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

December 18, 2023

Syndax Announces Proposed $150 Million Public Offering of Common Stock

December 13, 2023

Syndax Announces Pricing of $200 Million Public Offering of Common Stock

December 13, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 43 decks. Every deck is listed under its year.